Allegro raises €5,5M in funding to bring their innovative treatment for osteoarthritis into clinical trials
Allegro updated this press release on April 20, 2026, to refine certain statements in accordance with regulatory guidelines.
Allegro, The Belgian specialist in biomedical nanotechnology is excited to announce the closing of a €5,5M funding round, led by prominent life sciences investors Annie Vereecken and Noshaq, joined by SPW, family offices, and the company’s founders. The funds will be used to complete the pre-clinical and first-in-human phases of their innovative treatment for osteoarthritis.
An innovative investigational treatment for osteoarthritis
Osteoarthritis (OA) is a complex disease, whereby the joint’s mechanics have been overlooked for decades, instead focusing solely on the inflammation. Allegro believes that focusing on the joint mechanics is the best approach, which led to the development of the first causal treatment with potentially far-reaching benefits for the patient.
Allegro developed a completely new and unique hydrogel injection, which features revolutionary nanotechnology. The product aims to restore the mechanics of the joint, which is the fundamental cause of osteoarthritis. This new approach is supported by extensive preclinical studies supporting further clinical evaluation. Considering the current treatment landscape, the unmet clinical need, and the expected performance of the product, the company has a potential blockbuster in osteoarthritis.
5,5M for a potential blockbuster
Preclinical studies have shown encouraging safety and efficacy of the investigational hydrogel technology in the treatment of osteoarthritis including the potential to improve the visco-elasticity of synovial fluid compared to selected comparators.
Encouraging results should now be confirmed by completing the pre-clinical phase and starting a first-in-human study for its investigational hydrogel treatment for osteoarthritis. The proceeds also allow for building out the pipeline in orthopedics and chronic diseases. “This funding is a strong vote of confidence in Allegro’s technology and its potential to positively impact the life of patients with osteoarthritis”, declared Jorg Schelfhout, CSO and founder of Allegro.
Annie Vereecken, Investor, said: “Allegro’s founders are not only scientists with a deep knowledge of the product, but they have also a clear view on the (market) possibilities of the product in human and animal care. I am convinced that they will succeed in their intent together with the support of the investors.”
Hélène Sabatel, Investment Manager at Noshaq said: “Allegro is a young and dynamic start–up which is tackling a complex disease with significant unmet medical needs. They are developing a solution that could meet some of these needs and we are looking forward to confirm the promising potential of their product.”
The company is now hiring an additional 10 people, such as scientists in the field of biopolymers, and experts in clinical studies and quality management to shape the future of biomedical technology.
For more information please visit www.allegro.bio.
For further information please contact:
| Allegro NV Lucas Decuypere Chief Executive Officer email info@alllegro.bio | Investor Relations Mary-Ann Chang Cohesion Bureau +44 7483 284 853 mary-ann.chang@cohesionbureau.com Media Relations Douwe Miedema Cohesion Bureau +352 621 562 764 douwe.miedema@cohesionbureau.com |
Important information
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.